Julphar posts robust growth



Julphar Gulf Pharmaceutical Industries, the largest generic pharmaceutical manufacturer in Middle East and North Africa (MENA), announced it has closed the year 2015 at AED 1.47 billion, with a growth of 6 per cent against 2014 sales of 1.39 billion.

The company demonstrated a steady operational performance during 2015, posting 11.1 per cent year-on-year rise in its gross profits for the year ending 2015, which was AED 908.9 million. Julphar’s net profit for the period was AED 226.6 million, up 12.2 per cent year-on-year.

“2015 has been another year of great achievements for Julphar and we are excited to head into another stimulating year,” said Dr Ayman Sahli, Chief Executive Officer of Julphar.

Leave a Reply

Send this to a friend